EP2062890A1 — Tricyclic thrombin receptor antagonist
Assigned to Merck Sharp and Dohme LLC · Expires 2009-05-27 · 17y expired
What this patent protects
The bisulfate salt of the compound: and its use for the treatment of thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stoke, thromboembolic stroke, peripheral vascular di…
USPTO Abstract
The bisulfate salt of the compound: and its use for the treatment of thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stoke, thromboembolic stroke, peripheral vascular diseases, inflammatory disorders, cerebral ischemia or cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.